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D iabetes is a chronic, progressivelyworsening disease associated with avariety of microvascular and mac-
rovascular complications. Cardiovascular
disease (CVD) is the main cause of death
in these patients (1,2). During the past
decade, numerous drugs have been intro-
duced for the treatment of type 2 diabetes
that, used in monotherapy or in combina-
tion therapy, are effective in lowering
blood glucose to achieve glycemic goals
and in reducing diabetes-related end-
organ disease.
Two such drugs, rosiglitazone and
pioglitazone, belong to the class called
thiazolidinediones (TZDs) (3). Troglita-
zone, the first agent of this class to be ap-
proved, was effective in controlling
glycemia but was removed from the mar-
ket because of serious liver toxicity. Both
rosiglitazone and pioglitazone are indi-
cated either as monotherapy or in combi-
nation with a sulfonylurea, metformin, or
insulin when diet, exercise, and a single
agent do not result in adequate glycemic
control (4) (package insert Avandia [ros-
iglitazone maleate; GlaxoSmithKline] and
Actos (5) [pioglitazone hydrochloride;
Takeda Pharmaceuticals]). In addition to
lowering blood glucose, both drugs may
benefit cardiovascular parameters, such
as lipids, blood pressure, inflammatory
biomarkers, endothelial function, and fi-
brinolytic status (6,7).
These beneficial effects of TZDs on
glycemia and cardiovascular risk factors
have made them attractive agents in pa-
tients with type 2 diabetes who are at high
risk for CVD. There is a growing recogni-
tion, however, that edema can occur in
patients treated with either drug. Because
people with diabetes are at increased risk
for CVD and many have preexisting heart
disease, the edema that sometimes ac-
companies the use of a TZD can be cause
for concern, as it may be a harbinger or
sign of congestive heart failure (CHF). An
analysis of Medicare beneficiaries hospi-
talized with the diagnosis of diabetes and
CHF indicated that the number of these
patients discharged on TZDs had in-
creased from 7.2% to 16.2% over a 3-year
period (8). As the number of patients tak-
ing these drugs to control glycemia in-
creases, practitioners should be aware of
the safety profile of TZDs in patients with
and without underlying heart disease.
The clinical trials evaluating the safety
and efficacy of both TZD drugs excluded
subjects in New York Heart Association
(NYHA) class III or IV cardiac functional
status. In other words, patients with mod-
erate to severe limitation of physical activ-
ity due to symptoms of angina or CHF
during daily activities or at rest were not
enrolled. In addition, although these trials
did include patients with class I or II
NYHA cardiac status, it is not clear exactly
what percentage of the total patients stud-
ied fell into these latter two categories.
Also, clinicians or investigators may have
knowingly excluded patients with signif-
icant underlying heart disease. Regard-
less, there were very few serious cardiac
events in the short-term clinical trial data
submitted with the new drug applications
for either TZD.
Risk factors for CHF, such as coro-
nary artery disease and hypertension, fre-
quently occur in patients with diabetes
(1,9). These risk factors act synergistically
in diabetes to increase the risk for CHF.
Diabetes also may affect cardiac structure
and systolic or diastolic function, inde-
pendent of other established risk factors
for CHF, as a result of diabetic cardiomy-
opathy (10–12). Therefore, diabetes is a
strong and independent risk factor for
CHF. For example, an analysis of a large
number (n  9,591) of registrants with
type 2 diabetes in the Kaiser Permanente
Northwest Division demonstrated that
CHF was present in 11.8% of diabetic
subjects at baseline, and an additional
7.7% developed CHF over a 30-month
follow-up period (13). Clinicians should
be cognizant that CHF or left ventricular
dysfunction (systolic or diastolic) may be
present at the time TZDs are first pre-
scribed or may occur over time during
TZD treatment. Patients with type 2 dia-
betes who have significant underlying
asymptomatic heart disease may also be
prescribed these drugs, even though their
safety in such patients has not been fully
established.
The package inserts for both rosigli-
tazone and pioglitazone indicate that pa-
tients with more advanced heart disease
(class III or IV) were excluded in premar-
keting clinical trials, and hence, these
drugs are not recommended in such pa-
tients. At present, there are no guidelines
on the use of TZDs in patients with dia-
betes who have any degree of heart dis-
ease or for those already on a TZD who
develop CHF. Because edema is a more
frequent side effect of TZD therapy and by
itself is often a perplexing clinical di-
lemma with multiple causes (14), clini-
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cians may need guidance when edema (or
unexpected weight gain) is encountered
in a patient on a TZD. For these reasons,
the American Diabetes Association and
the American Heart Association assem-
bled a workgroup to evaluate the use of
TZDs in patients with preexisting heart
disease and in those who develop edema
or unexpected weight gain during the
course of TZD therapy. This statement is a
summary of the workgroup’s findings and
recommendations.
DEVELOPMENT OF WEIGHT
GAIN AND TZDS — In a 52-week
study comparing rosiglitazone to a sulfo-
nylurea (glyburide, median dose 7.5 mg/
day), a mean weight gain of 1.9 kg was
observed in both the sulfonylurea group
and the rosiglitazone group at the 4-mg
daily dose, and a 2.9-kg weight gain was
observed at the rosiglitazone 8-mg daily
dose (4). When coadministered with a
sulfonylurea in a 26-week study, rosigli-
tazone at 4 mg/day was associated with a
1.8-kg weight gain compared with sulfo-
nylurea alone. Similar weight gain has
been observed when rosiglitazone is
added to metformin. When added to in-
sulin therapy, however, weight gain may
be more dramatic. After 6 months of treat-
ment, weight gains of 4.1 kg and 5.4 kg
were encountered when rosiglitazone, at
the 4-mg and 8-mg daily doses, respec-
tively, was added to insulin (mean dose
70 units/day), compared with a weight
gain of1 kg in patients treated with in-
sulin alone (4). Similar increases have
been observed with pioglitazone, either as
monotherapy or in combination with
other hypoglycemic therapies, although
the duration of treatment was not identi-
cal (15). Compared with placebo, piogli-
tazone monotherapy caused median
weight gains of 0.9, 1.0, and 2.6 kg at the
15-, 30-, and 45-mg daily doses, respec-
tively (5). Median weight gains of 2.3 and
3.6 kg occurred when pioglitazone at 15
and 30 mg daily was added to insulin. In
contrast to trials with rosiglitazone, which
included changes in weight gain at rosigli-
tazone’s highest recommended daily dose
(8 mg), the clinical trial data submitted to
the U.S. Food and Drug Administration in
support of pioglitazone did not include
data on weight gain at its highest recom-
mended daily dose of 45 mg when coad-
ministered with sulfonylurea, metformin,
or insulin, although these data have re-
cently been cited. Thus, the weight gain
associated with TZD use seems to be dose
dependent, although in one 4-month ran-
domized open-label trial, similar in-
creases in body weight ( 2 kg) were seen
across the entire dose ranges of rosiglita-
zone (2 to 8 mg/day) and pioglitazone (15
to 45 mg/day) (16).
The weight gain associated with the
use of TZDs is probably due to several
interacting factors. In general, improve-
ment in glycemic control with decreased
glycosuria and caloric retention may re-
sult in increased weight. Several studies
have shown that the weight gain with
TZDs may be associated with an increase
in subcutaneous adipose tissue and a con-
comitant decrease in visceral fat; although
subcutaneous fat area increases, visceral
fat area and the ratio of visceral to subcu-
taneous fat decrease (17,18). This change
in fat distribution may explain in part the
improvement in glycemic control despite
an overall increase in body weight (19). A
decrease in leptin levels and an increase in
appetite have been seen with troglitazone
treatment (20); however, it is not clear if
weight gain associated with rosiglitazone
or pioglitazone can be attributed to this
effect. Fluid retention, of course, is an-
other potential cause of increased body
weight. TZDs, whether administered
alone or in combination with metformin,
sulfonylurea, or insulin, are often accom-
panied by an increase in plasma volume.
In healthy volunteers who received ros-
iglitazone (8 mg once daily) for 8 weeks,
there was a small but statistically signifi-
cant increase in mean plasma volume of
1.8 ml/kg compared with placebo (4).
For rosiglitazone, the fall in hemoglobin
ranged from 0.8 to 1.1 g/dl (with a similar
fall in hematocrit ranging from 2.3% to
3.6%) relative to whether the drug was
used as monotherapy or combination
with other oral agents or insulin (4). Sim-
ilar decreases in hemoglobin have been
observed with pioglitazone (5). These
changes in weight gain and blood profile
are usually observed during the first
weeks of therapy and plateau thereafter.
No clinically significant changes in other
cellular components of blood have been
seen, nor has an increase in red blood cell
turnover been demonstrated, which sug-
gests that TZDs have no effect on erythro-
poiesis (21,22). Thus, the changes in
hemoglobin and hematocrit may reflect,
in part, hemodilution resulting from in-
creased plasma volume. With an increase
in plasma volume, mild to moderate
edema and CHF might be anticipated side
effects of treatment with these drugs, de-
pendent to some degree on whether TZDs
are used in conjunction with insulin (see
below) and on the presence and degree of
concomitant heart disease.
DEVELOPMENT OF EDEMA
AND TZDS — When used as mono-
therapy, the incidence of pedal edema
ranges from 3% to 5% for each of the
TZDs. The incidence is greater when the
drugs are used in combination with other
glucose-lowering agents. In the U.S. pla-
cebo-controlled trials, edema occurred in
4.8% of subjects on pioglitazone mono-
therapy, versus 1.2% on placebo (23).
When pioglitazone was combined with
sulfonylureas, edema was noted in 7.5%
of patients compared with 2.1% on sulfo-
nylureas alone. Edema was seen in 6.0%
of patients on a pioglitazone/metformin
combination versus 2.5% on metformin
alone (24,25). In double-blind trials with
rosiglitazone, the incidence of edema was
4.8% in the rosiglitazone group com-
pared with 1.3% on placebo. When com-
bined with metformin or sulfonylurea,
edema was observed in 3% to 4% of pa-
tients compared with 1.1% to 2.2% on
either comparator drug alone (4). These
data suggest that edema is a side effect of
each of the TZD drugs to a similar degree,
either when used as monotherapy or
when combined with other oral diabetes
agents. Edema is more common when the
TZD is used in combination therapy.
Practitioners are most likely to see
edema as a consequence of TZD therapy
when either of the TZDs is used in com-
bination with insulin. For example, ros-
igl i tazone 4 or 8 mg per day in
combination with insulin was associated
with a 13.1% and 16.2% incidence of
edema, respectively, compared with 4.7%
in those taking insulin alone (26). Piogli-
tazone at 15 mg or 30 mg daily in combi-
nation with insulin resulted in a
combined 15.3% incidence of edema,
compared with 7.0% for insulin alone
(27). Therefore, the incidence of edema is
higher when either of the TZDs is com-
bined with insulin, compared with when
TZDs are used in combination therapy
with additional oral hypoglycemic agents.
It should be noted, however, that edema
occurs more often in patients treated with
insulin than in patients on other oral hy-
poglycemic drugs. Type 2 diabetes pa-
tients on insulin usually have had
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diabetes for many years and thus are
likely to be older and have a greater prev-
alence of hypertension, left ventricular
hypertrophy, and a history of coronary
artery disease—all conditions more likely
to be associated with edema. Indeed,
among 166 diabetic patients treated with
TZD who had numerous comorbid con-
ditions and were monitored at a Veterans
Affairs Clinic over 14 months, edema de-
veloped in 18.1%. Baseline azotemia,
prior CHF, and coronary artery disease
were common in this group (28). The
prevalence of background CHF in pa-
tients treated with insulin alone may also
be higher than in patients not receiving
insulin (2.5% in some rosiglitazone trials)
(28,29). thereby contributing to a higher
incidence of edema when a TZD is added
to insulin compared with other glucose-
lowering agents. Although the TZDs have
not been compared with each other at
equipotent dosages, the incidence of
edema was similar when either drug was
combined with other hypoglycemic drugs
in a short-term, nonrandomized clinical
study (16).
PATHOGENESIS OF EDEMA
WITH TZD USE — The reasons for
fluid retention and peripheral edema with
TZD use are not fully understood and are
likely to be multifactorial. The increase in
plasma volume related to TZDs has al-
ready been cited and may result from a
reduction in renal excretion of sodium
and an increase in sodium and free water
retention (30). TZDs may interact syner-
gistically with insulin to cause arterial va-
sod i l a t a t ion , l ead ing to sod ium
reabsorption with a subsequent increase
in extracellular volume, and thereby re-
sulting in pedal edema. Increased sympa-
thetic nervous system activity (31),
altered interstitial ion transport (32), al-
terations in endothelial permeability (33),
and peroxisome proliferator–activated re-
ceptor-–mediated expression of vascu-
lar permeability growth factor (34)
represent other possible mechanisms for
edema with these agents.
TZDS AND CHF — In clinical trials
using TZDs, CHF was not frequently en-
countered. The incidence of CHF was
1% for rosiglitazone monotherapy or
when rosiglitazone was added to sulfonyl-
urea or metformin, and was similar to that
observed during treatment with a placebo
(4). When rosiglitazone at either 4 or 8
mg/day was added to insulin therapy,
however, CHF increased to 2% and 3% of
the study population, respectively, com-
pared with 1% in the group treated with
insulin alone (4). It is important to note
that preexisting microvascular and car-
diovascular comorbidity was more preva-
lent in those clinical trials in which
rosiglitazone was added to insulin ther-
apy than in those trials in which rosiglita-
zone was either used alone and compared
with placebo or combined with met-
formin or sulfonylureas. The patients who
developed CHF on rosiglitazone plus in-
sulin were also older and had diabetes of
longer duration.
The data on pioglitazone are some-
what similar. In a placebo-controlled trial
(5), 2 of 191 patients (1.1%) receiving 15
mg pioglitazone plus insulin and 2 of 188
(1.1%) patients receiving pioglitazone
(30 mg) plus insulin developed CHF,
compared with none of the 187 patients
receiving insulin alone. All four of these
patients had underlying coronary artery
disease.
The rosiglitazone and pioglitazone
trials are not entirely comparable, as the
rosiglitazone maximum recommended
daily dose (8 mg/day) was evaluated in
the rosiglitazone trials, whereas pioglita-
zone was not evaluated at its highest dose
of 45 mg/day when combined with other
hypoglycemic agents. Also, here too, the
duration of treatment differed apprecia-
tively—26 weeks with rosiglitazone and
16 weeks with pioglitazone. It is unlikely,
however, that the drugs differ with regard
to the risk of CHF, as they incur similar
degrees of volume expansion. In sum-
mary, the incidence of CHF in TZD-
treated patients is very low but is
definitely higher in patients already
treated with insulin who receive higher
doses of the TZD and who have other risk
factors for CHF.
PATHOGENESIS OF CHF
WITH TZD USE — The peripheral
edema or CHF associated with the use of
the drugs would suggest that an increase
in plasma volume is the main culprit, ei-
ther alone or superimposed on preexist-
ing heart disease. The effect of TZDs on
cardiac structure and function has been
reported in a few studies. An increase in
left ventricular mass as an adaptation to
volume expansion has been noted in ani-
mals given long-term troglitazone admin-
istration at doses exceeding those used in
the clinical setting (35). In clinical trials,
however, treatment with troglitazone did
not result in any significant change in left
ventricular mass after 48 weeks of obser-
vation (36). In a recent study (37), 203
patients were randomly assigned to either
rosiglitazone (4 mg b.i.d.) or glyburide
(mean dose 10.5 mg q.d. and titrated to
20 mg/day). An echocardiogram was
performed on 118 of these patients before
and 52 weeks after treatment to assess left
ventricular mass index, ejection fraction,
and end-diastolic volume. Neither drug
produced an increase in left ventricular
mass index that exceeded one standard
deviation or a decrease in left ventricular
ejection fraction in either group, and both
drugs were associated with clinically in-
significant increases in left ventricular
end-diastolic volume. Fluid retention re-
sulting in increased plasma volume was
thought to explain the small but insignif-
icant increase in left ventricular end-dia-
stolic volume seen with rosiglitazone in
this study. Similarly, a preliminary report
(38) using pioglitazone evaluated cardiac
mass and function in patients with type 2
diabetes in a long-term, open-label study.
Pioglitazone to a maximum dose of 60 mg
q.d. for up to 48 weeks had no adverse
effect on cardiac structure and function as
evaluated by echocardiography. Unfortu-
nately, there are no published data on car-
diac structure and function in patients on
long-term TZD therapy who have preex-
isting left ventricular dysfunction or who
develop an acute coronary event while re-
ceiving TZD therapy. There are, however,
animal studies suggesting that TZDs may
have a beneficial effect on left ventricular
remodeling and function after ischemic
injury (39,40).
The effect of rosiglitazone on the left
ventricular response to ischemia has been
assessed in an ischemia-reperfusion
model in experimental animals. When
rosiglitazone was administered immedi-
ately before an episode of ischemia, the
full recovery of left ventricular function
after reperfusion was more rapid com-
pared with control animals (39). A recent
study has also demonstrated that piogli-
tazone improved left ventricular remod-
eling and partially normalized systolic
function in mice after extensive anterior
myocardial function (40). These cardio-
protective effects of TZDs are indepen-
dent of glucose lowering and may be due
to antioxidant, anti-inflammatory, or cal-
cium channel–blocking properties of the
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drugs. Hence, it is possible that TZDs may
have direct effects on cardiac muscle that
prevent heart failure in the setting of acute
ischemia.
CLINICAL PRACTICE
EXPERIENCE WITH TZDS — Ep-
idemiological studies have also examined
the relationship between TZDs and the
risk of CHF. Delea and coworkers (41), in
a retrospective, observational study of
health insurance claims, determined the
risk of heart failure among diabetic pa-
tients prescribed TZDs over a 5-year pe-
r iod (1996 –2001) , wi th a mean
follow-up period of 8.5 months. The risk
of heart failure was 4.5% in the groups
exposed to TZDs and 2.6% in those not
exposed to a TZD. The increased risk
(hazard ratio of 1.6, P  0.001) persisted
after adjustment for potential confound-
ers, including age, history of complica-
tions of diabetes, risk factors for CHF, and
use of various medications for diabetes or
CHF. Increased risk was also associated
with advanced age, history of coronary
artery disease, diabetes-related end-organ
disease, and the use of angiotensin-
converting enzyme inhibitors, -block-
ers, or insulin.
In another preliminary report by
Karter and coworkers (42), using the Kai-
ser Permanente Northern California Reg-
istry, the incidence of CHF was evaluated
in 27,000 patients with diabetes not
previously treated with oral hypoglyce-
mic drugs who were prescribed pioglita-
zone or other glucose-lowering drugs in a
nonrandomized manner and monitored
for 1.5 years in a prospective, observa-
tional cohort study. Overall, 74 (0.2%) of
the 24,973 subjects without prior history
of CHF experienced a first episode of
CHF, and 69 (3.5%) of the 1,964 patients
with a history of CHF experienced a sub-
sequent bout. Compared with patients
given a sulfonylurea, the hazard ratio for
CHF in patients receiving pioglitazone
was 1.8. Patients in this study treated with
pioglitazones or insulin, either alone or in
combination, had a higher risk profile for
CHF before initiation of glucose-lowering
therapy. Such patients also were more
likely to have diabetes of longer duration,
a history of hypertension, or microalbu-
minuria or to be treated for hyperlipid-
emia. When adjusted for risk factors
associated with heart failure as well as de-
terminants of diabetes severity and socio-
economic status, the TZD hazard ratio
decreased to 1.2 and was similar to that of
insulin combined with other oral hypo-
glycemic agents. The risk for recurrent
heart failure in those subjects in whom a
diagnosis of CHF had been made in the 5
years before implementation of glucose-
lowering therapy was not significantly el-
evated in the pioglitazone group or in the
group treated with insulin in combination
with either metformin or sulfonylurea,
compared with those given a sulfonyl-
urea. These authors concluded that the
risk profiles of patients initiated on pio-
glitazone therapy (or on insulin) identi-
fied them as being at increased risk for
CHF before TZD treatment was begun
and that there appeared to be no signifi-
cant increase in CHF with pioglitazone
treatment after adjusting for preexisting
disease severity.
This Karter study suggests that de-
spite the common occurrence of edema
with TZDs, the excess risk of CHF attrib-
utable to the TZD itself in relative terms is
very small. A report from the Cleveland
Clinic (43) evaluated the occurrence and
characteristics of fluid retention in an ob-
servational analysis of patients with type 2
diabetes, class I to III CHF, and a docu-
mented ejection fraction of 45% who
were treated with troglitazone, rosiglita-
zone, or pioglitazone over a 2-year pe-
riod. Of the 111 subjects, 19 (17.1%)
developed fluid retention, defined as a
weight gain of10 lb associated with pe-
ripheral edema. Of these 19, 6 (5.4%)
manifested worsening jugular venous dis-
tension, and 2 experienced pulmonary
edema. Fluid retention was related to fe-
male gender and concomitant insulin use
but not related to degree of underlying
CHF severity. Although not a prospective
study, this study suggested that despite
posing a “significant” risk for edema,
TZDs could be used in diabetic patients
with “stable” CHF as long as they are
closely monitored for signs of fluid over-
load. Several clinical trials are underway
that will help define the level of risk for
CHF in TZD-treated patients. Many of
these prospective controlled studies have
predetermined cardiovascular end points
and are being carried out in subjects with
impaired glucose tolerance or type 2 dia-
betes with and without underlying heart
disease.
Despite the low incidence of CHF in
clinical trials and cohort studies, there
have been a small number of case reports
that have described CHF in these patients
treated with TZDs (28,44–48). These re-
ports are noteworthy inasmuch as TZDs
were used in patients with diabetes and a
wide spectrum of background cardiovas-
cular conditions, and this experience
could illustrate what may be encountered
in clinical practice. In these reports, CHF
occurred in patients with either depressed
or normal systolic function and was usu-
ally encountered when the TZD was used
in combination with insulin. In most
cases, the onset of CHF was preceded by
the appearance of edema after initiation of
TZD treatment. CHF in the setting of nor-
mal systolic function may be particularly
common in the setting of diabetes, as di-
abetes may decrease left ventricular com-
pl iance even in the absence of
hypertension and ischemic heart disease.
Considering the volume sensitivity of
such patients, a new diagnosis of CHF in a
patient recently begun on TZDs could be
attributable to the increase in plasma vol-
ume unmasking previously asymptomat-
ic and unrecognized diastolic dysfunction.
These case reports indicate that signifi-
cant CHF can occur and may be directly
attributable to TZD therapy. Although
warnings exist on the use of TZDs in pa-
tients with significant heart disease, clini-
cians should be aware that CHF can
sometimes occur in the patient with dia-
betes who otherwise appears to be at low
risk for such adverse events. Despite these
reports and the possibility of underre-
porting of drug-related adverse events or
side effects, the risk of CHF seems to be
very low, given the number of patients
treated with TZDs.
RECOMMENDATIONS — On con-
sideration of the above information, the
workgroup recommends the following
(see Fig. 1):
Before TZD treatment, the physician
should:
A. Ascertain whether the patient has un-
derlying cardiac disease—i.e., previ-
ous myocardial infarction or other
evidence of coronary artery disease,
prior episodes of CHF, or significant
aortic or mitral valve disease.
B. Note whether the patient is taking any
drugs associated with fluid retention
(e.g., vasodilators, nonsteroidal anti-
inflammatory drugs) or pedal edema
(e.g., calcium channel– blocking
drugs).
C. Evaluate the pathogenesis of edema
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that may be already present to be sure
that CHF is not present at the time the
TZD is prescribed. The presence of
edema, when not caused by CHF, is
not a contraindication for TZD use.
However, if present, the degree of
edema should be monitored carefully
during TZD administration.
D. Determine whether the patient has
any shortness of breath, particularly
with exertion, that might be due to
cardiac or other causes (e.g., asthma,
chronic obstructive pulmonary dis-
ease, obesity) so that an adequate as-
sessment of baseline symptoms is
established. Patients with these symp-
toms should be monitored carefully,
particularly in the first 3 months of
TZD treatment.
E. Review most recent ECG, if indicated.
The ECG may show a clinically silent
myocardial infarction or left ventricu-
lar hypertrophy—two conditions that
are risk factors for CHF.
F. Instruct the patient before initiation of
TZD to report any new sign or symp-
tom during the course of treatment,
such as weight gain 3 kg, pedal
edema (particularly if the onset is
acute and the amount progresses rap-
idly), shortness of breath, or fatigue
without other apparent cause.
Use of TZDs in Patients With
Diabetes and Without Symptomatic
Heart Disease
● In patients without established heart
disease, both pioglitazone and rosiglita-
zone should be prescribed according to
the package insert guidelines for each
drug. It should be recognized that
weight gain and/or edema will be en-
countered more often in patients on
concomitant insulin treatment.
● When a TZD is prescribed to patients
who do not have established heart dis-
ease but have one or more risk factors
for CHF (see Table 1), one should con-
sider starting with low doses (e.g., ros-
iglitazone 4 mg q.d. or pioglitazone 15
mg q.d.) and increase the dosage grad-
ually as required to optimize glycemic
control, while observing for any signs of
excessive weight gain, peripheral
edema, or CHF.
● In patients who do not have symptoms
or signs of CHF but are known to have
Figure 1
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a depressed ejection fraction (e.g.,
40%), TZDs may be used at the lower
dosage range of each drug. Dosages can
be adjusted gradually after several
months of treatment to optimize glyce-
mic control with careful observation for
edema and symptoms and signs of
CHF. It is not uncommon for patients
with diabetes without symptomatic
heart disease to have had determina-
tions of left ventricular function with
noninvasive cardiac testing in the
course of screening for coronary artery
disease or as part of a preoperative eval-
uation for surgical procedures. This
recommendation is presented because
patients with depressed cardiac func-
tion are at higher risk for CHF due to
fluid retention from any cause, despite
the absence of cardiac symptoms. The
results of ongoing clinical trials will
help to determine the safety of TZD use
in these patients.
Use of TZDs in Patients With
Diabetes and Symptomatic Heart
Disease
● In patients with class I or II NYHA CHF
categories, TZDs may be used cau-
tiously, with initiation of treatment at
the lower dosage of each drug (e.g., ros-
iglitazone 2 mg q.d. or pioglitazone 15
mg q.d.). Observation with gradual
dose escalation is warranted to identify
weight gain, edema, or an exacerbation
of CHF. One should allow more time
than usual to achieve a target HbA1c in
these patients. Ongoing clinical trials
will help to establish the safety of TZD
use in these patients.
● In patients with symptoms and signs of
NYHA class III or IV CHF, TZDs should
not be used at this time.
Monitoring Patients on TZD Therapy
● Once on TZDs, patients should be in-
structed to monitor for weight gain or
the presence of pedal edema. If edema
develops, particularly within the first
few months of TZD therapy, the physi-
cian should determine whether CHF is
present. Symptoms suggestive of CHF
may include orthopnea, paroxysmal
nocturnal dyspnea, unexplained cough
or fatigue, or pedal edema. A physical
examination should be performed to
determine if there are signs of CHF
(e.g., jugular venous distention, an S3
gallop, pulmonary rales). Pedal edema
in conjunction with any of these symp-
toms or signs may indicate that the
edema is a manifestation of CHF even
in the absence of a prior history of heart
disease. A noninvasive cardiac evalua-
tion including an ECG and echocardio-
gram should also be performed, and
brain natriuretic peptide measurement
may also be helpful. Even in the ab-
sence of prior cardiac disease, such an
evaluation may reveal changes in car-
diac function that have occurred during
the course of TZD treatment. An exer-
cise tolerance test or stress imaging
(echo or perfusion) study may also be
indicated if any of the symptoms are
thought to be ischemic in origin.
● If edema occurs and CHF is not present
during TZD therapy, other causes of the
edema should be investigated before at-
tributing it to the TZD. For example,
other drugs associated with pedal
edema or venous insufficiency may be
responsible. The presence of edema
with prior proteinuria may indicate ne-
phrotic syndrome. Diuretics may be
prescribed or the dose of diuretic in-
creased (when prescribed as an antihy-
pertensive agent) for those patients
who do not tolerate pedal edema, al-
though the effectiveness of diuretics in
TZD-related edema may be variable.
Several studies have suggested that the
addition of an angiotensin-converting
enzyme inhibitor with or without a thi-
azide diuretic may reduce the edema
associated with dihydropyridine cal-
cium channel blockers. To the extent
that “vasodilatory” edema also occurs
with TZDs, this strategy may be helpful
(49,50). In this situation also, the dose
of TZD might be lowered or alternative
drugs to control glycemia instituted.
● If a new diagnosis of CHF is made or
considered likely, even in the absence
of prior left ventricular dysfunction, the
use of the TZD should be reconsidered.
Dosage change and temporary or per-
manent discontinuance are the obvious
options, but no one of these is preferred
for all patients. Treatment directed to
CHF should be initiated according to
current guidelines (51). In the absence
of systolic dysfunction, only diuretics
such as furosemide may be necessary.
The duration of diuretic therapy can be
quite variable, as the need for diuresis
may be temporary if the patient im-
proves and fluid retention disappears
with the discontinuation of the TZD.
● For patients with known left ventricu-
lar dysfunction who develop CHF
while on a TZD, the drug should be
discontinued, and therapy with diuret-
ics, angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers,
-blockers, and digoxin should be con-
sidered and titrated according to the se-
verity of the patient’s condition and
current treatment guidelines for CHF.
CONCLUSIONS — The pr ima ry
treatment goal in type 2 diabetes is resto-
ration and maintenance of normoglyce-
mia and the prevention of CVD. The
range of therapeutic options has been ex-
tended with the introduction of TZDs
used as monotherapy or in combination
with oral hypoglycemic drugs or insulin.
There is substantial interest in whether
these agents may reduce or modify risk of
CVD through a wide range of peroxisome
proliferator–activated receptor-–
mediated effects on the cardiovascular
system, in addition to their recognized ef-
ficacy as glucose-lowering drugs to treat
type 2 diabetes (6,7).
Edema is a recognized side effect of
these drugs, particularly when combined
Table 1—Risk factors for heart failure in patients treated with TZDs
1. History of heart failure (either systolic or diastolic)
2. History of prior myocardial infarction or symptomatic coronary artery disease
3. Hypertension
4. Left ventricular hypertrophy
5. Significant aortic or mitral valve heart disease
6. Advanced age (70 years)
7. Long-standing diabetes (10 years)
8. Preexisting edema or current treatment with loop diuretics
9. Development of edema or weight gain on TZD therapy
10. Insulin coadministration
11. Chronic renal failure (creatinine 2.0 mg/dl)
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with insulin. Both patients and health
care providers should be cognizant of the
risk of CHF when TZDs are used in pa-
tients with type 2 diabetes. Prospective
clinical trials are currently underway to
ascertain the cardiovascular safety of
TZDs in patients with diabetes and under-
lying heart disease.
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